Assessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial

This open-label feasibility trial demonstrates that personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) induces rapid and sustained antidepressant effects in patients with both treatment-resistant and ultra-treatment-resistant depression, offering a safe and effective option for individuals who have failed multiple prior therapies.

The Gist

Imagine your brain is like a massive, bustling city with billions of roads (neurons) and traffic lights (synapses) controlling the flow of information. In Treatment-Resistant Depression (TRD), it's as if the city is stuck in a permanent, heavy fog. The traffic lights are broken, the roads are clogged, and no matter how many different "traffic controllers" (medications, therapy, or standard brain stimulation) you hire, the fog just won't lift. For some people, this fog is so thick they are "Ultra Treatment-Resistant" (UTRD)—meaning they've tried almost everything, and nothing has worked.

This paper describes a new experiment called the PRISM-UTRD trial that tried a different approach to clear that fog. Here is the story of what they did, explained simply:

1. The Old Way vs. The New Way

Think of standard brain stimulation (rTMS) like a generic street sweeper. It drives down the main avenues, hoping to clean up the mess. It works for some, but if the city is really broken, a generic sweeper might miss the specific alleyways where the real problems are hiding.

The researchers in this study used a high-tech, GPS-guided drone.

• The GPS: Before starting, they took a special 3D map (an fMRI scan) of each patient's brain. This map showed exactly which "roads" were disconnected or broken for that specific person.
• The Drone: Instead of a generic sweep, they used a machine called iTBS (a type of magnetic stimulation) that targeted those exact broken spots.
• The Speed: Usually, these treatments take weeks, like watering a garden slowly over a month. This study used an "accelerated" protocol, meaning they crammed 8 treatments into just 5 days. It was like giving the garden a massive, concentrated burst of water all at once to wake it up immediately.

2. The Experiment

They gathered 73 people who were stuck in that deep depression fog.

• Group A: People who had tried many treatments but failed (TRD).
• Group B: People who had tried everything and were considered "Ultra" resistant (UTRD).

They gave both groups the "GPS-guided drone" treatment for 5 days straight.

3. The Results: The Fog Lifts

The results were like watching the sun break through a storm cloud:

• Rapid Improvement: By the end of the 5 days, the average patient's depression score dropped significantly. It wasn't a slow climb; it was a fast recovery.
• Everyone Benefited: Surprisingly, it didn't matter if you were in the "regular resistant" group or the "ultra resistant" group. The "GPS drone" worked for both. The "Ultra" group, who were expected to be the hardest to help, got just as much relief as the others.
• Long-Lasting: The improvement didn't vanish the next day. It lasted for at least 12 weeks after the treatment stopped.
• More Than Just Mood: Patients also reported feeling better in other areas, not just their sadness. It was like the whole city started functioning again, not just the main square.

4. Why This Matters

Think of this treatment as a reset button for the brain's traffic system.

• For people who have tried everything else, this offers a new hope.
• It is safe and well-tolerated (very few people had to quit because of side effects).
• Because it works so fast (5 days instead of 6 weeks), if it doesn't work for someone, they don't have to wait months to try the next option. They can move on quickly.

The Bottom Line

This study showed that by using a personalized map to target the brain's specific broken connections, and by delivering the treatment fast and intense, doctors can clear the depression fog even for the most stubborn cases. It's a promising new tool that says: "Even if the city is broken, we can find the exact broken road and fix it, no matter how deep the fog is."

Technical Summary

1. Problem Statement

Conventional repetitive transcranial magnetic stimulation (rTMS) often fails to produce therapeutic effects in patients with Treatment-Resistant Depression (TRD), particularly those who have previously failed brain stimulation, ketamine therapy, or multiple pharmacological lines of treatment. This subgroup, often termed Ultra-Treatment-Resistant Depression (UTRD), represents a critical clinical gap. While modern accelerated rTMS protocols utilizing image-guided targets exist, they have not been systematically investigated in these highly refractory populations. The study aims to address whether personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) can effectively reduce depression severity in patients across the spectrum of TRD, including the most severe UTRD cases.

2. Methodology

• Study Design: An open-label feasibility trial conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre (Toronto, Canada).
• Participants:
  • Total Screened: 96 patients with Major Depressive Disorder.
  • Enrolled: 73 eligible participants (30 classified as UTRD, 43 as TRD).
  • Exclusions: Two participants withdrew (one due to MRI intolerance, one voluntary).
• Intervention:
  • Protocol: Neuronavigated, accelerated iTBS (600 pulses per session).
  • Targeting: Personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI) connectivity mapping.
  • Schedule: Eight daily treatments administered over five consecutive days.
• Outcome Measures:
  • Primary: Change in the 17-item Hamilton Depression Rating Scale (HAM-D17) from baseline to Day 5.
  • Secondary: Comparison of HAM-D17 changes between UTRD and TRD subgroups; response and remission rates; self-report scales for broader symptomatic relief.
  • Follow-up: Assessments conducted immediately post-treatment, and at 4 and 12 weeks.

3. Key Contributions

• First Systematic Investigation in UTRD: This study is the first to systematically evaluate accelerated, connectivity-guided iTBS specifically in a cohort of patients with ultra-treatment-resistant depression who have failed multiple prior modalities.
• Personalized Connectivity Targeting: It validates the use of fMRI-derived, individualized dlPFC targets (clustered around the anterolateral region) rather than standard anatomical coordinates.
• Feasibility of Accelerated Protocols: It demonstrates the safety and tolerability of an intensive 5-day accelerated schedule in a highly refractory population.
• Stratified Analysis: The study explicitly compares outcomes between standard TRD and UTRD, addressing whether the severity of resistance impacts the efficacy of this specific intervention.

4. Results

• Targeting Precision: Connectivity-guided fMRI successfully generated personalized targets clustered around the anterolateral dlPFC.
• Efficacy (Primary Outcome):
  • Rapid Antidepressant Effect: Significant reduction in HAM-D17 scores was observed immediately after the 5-day treatment ($\Delta$HAM-D17 = -9.01, SD 6.06; $t = -12.45$, $p < 0.001$).
  • Sustainability: These improvements were sustained through the 12-week follow-up.
• Subgroup Analysis:
  • There was no statistically significant difference in treatment response between the UTRD and TRD groups ($\Delta$HAM-D17 -9.64 vs. -8.10; $t = -1.05$, $p = 0.299$). This indicates that the accelerated protocol was equally effective for the most refractory patients.
• Clinical Rates:
  • Response Rate: 40.8% at the end of treatment.
  • Remission Rate: 16.9% at the end of treatment.
• Broader Benefits: Self-report scales indicated symptomatic relief extending beyond core depressive symptoms.

5. Significance

The PRISM-UTRD trial establishes that connectivity-guided, accelerated iTBS is a viable, safe, and effective intervention for patients across the entire spectrum of treatment resistance, including those deemed "ultra-resistant."

• Clinical Impact: It offers a therapeutic option for a population unlikely to respond to standard antidepressants or conventional rTMS.
• Efficiency: The accelerated 5-day protocol allows for rapid assessment of efficacy. If the treatment fails, patients can expeditiously proceed to subsequent therapies (e.g., ECT or novel agents) without the delay associated with conventional 6-week rTMS courses.
• Future Direction: The findings support the integration of functional connectivity mapping into routine rTMS targeting to maximize efficacy in complex, refractory depression cases.